Lucid Diagnostics (LUCD) said Friday it closed its public offering of about 14.4 million common shares, including roughly 1.9 million shares issued pursuant to the exercise of the underwriters' overallotment option, at $1.20 per share.
The net proceeds of about $16.1 million will be used for working capital and general corporate purposes, according to the company, which is a unit of PAVmed (PAVM).
Price: 1.23, Change: -0.02, Percent Change: -2.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.